Evolocumab Reduces First Major Cardiovascular Events in High-Risk Patients Without Known Significant Atherosclerosis
In high-risk patients with diabetes but no known significant atherosclerosis, treatment with evolocumab significantly reduced the risk of a first major cardiovascular event compared with placebo when added to statin therapy. This prespecified subgroup analysis of the VESALIUS-CV randomized, double-blind, placebo-controlled trial included 3,655 participants from 774 sites across 33 […]